<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20231122131058&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20231122131058&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 22 Nov 2023 18:11:00 +0000</lastbuilddate>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>High-Sensitivity Troponin in Pulmonary Embolism Risk Stratification-Proceed With Caution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4363. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37991786</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4363>10.1001/jamacardio.2023.4363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991786</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>High-Sensitivity Troponin in Pulmonary Embolism Risk Stratification-Proceed With Caution</dc:title>
<dc:identifier>pmid:37991786</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4363</dc:identifier>
</item>
<item>
<title>High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this study of patients with hemodynamically stable PE, hs-cTnI identified modest elevations in cardiac troponin levels. However, the results did not provide additive clinical value compared with cTnI. These findings suggest that use of hs-cTnI may result in overestimation of the risk in patients with stable PE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: High-sensitivity troponin tests can detect even milder cardiac troponin elevations in plasma, beyond the threshold of conventional troponin tests. Whether detection of low-grade cardiac troponin elevation is associated with outcomes of patients with hemodynamically stable pulmonary embolism (PE) and helps with risk stratification is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the association between high-sensitivity cardiac troponin I (hs-cTnI) compared with conventional cardiac troponin I (cTnI) and PE risk designations according to the European Society of Cardiology (ESC) 2019 classification scheme and clinical outcomes in patients with hemodynamically stable PE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of data from the prospective Prognostic Value of Computed Tomography (PROTECT) multicenter cohort study enrolling patients from 12 hospital emergency departments in Spain. In this analysis, cTnI and hs-cTnI were compared with respect to ESC risk designation, and the association between troponin values and a complicated course after PE diagnosis was evaluated. Of 848 patients enrolled in PROTECT, 834 (98.3%) had hsTnI and cTnI values available and were included in the present analysis. Data were analyzed from May to December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Troponin blood testing with cTnI (threshold of >;0.05 ng/mL) vs hs-cTnI (threshold of >;0.029 ng/mL) assays at the time of PE diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES: Complicated course, defined as hemodynamic collapse, recurrent PE, or all-cause death, within 30 days after PE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 834 patients (mean [SEM] age, 67.5 [0.6] years; 424 [50.8%] female), 139 (16.7%) had elevated cTnI and 264 (31.7%) elevated hs-TnI, respectively. During follow-up, 62 patients (7.4%; 95% CI, 5.7-9.4) had a complicated course. Analyzing troponin elevation as a binary variable, elevated cTnI (odds ratio [OR], 2.84; 95% CI, 1.62-4.98) but not hs-cTnI (OR, 1.12; 95% CI, 0.65-1.93) was associated with increased odds of a complicated course. Of 125 patients who had elevated hs-cTnI but normal cTnI, none (0; 95% CI, 0.0-2.9) developed a complicated course. Using the 2019 ESC risk stratification scheme, hs-TnI classified fewer patients as low risk compared with cTnI. Among 78 patients designated as ESC low risk when using cTnI but not with hsTnI, none (0; 95% CI, 0.0-4.6) had a complicated course.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study of patients with hemodynamically stable PE, hs-cTnI identified modest elevations in cardiac troponin levels. However, the results did not provide additive clinical value compared with cTnI. These findings suggest that use of hs-cTnI may result in overestimation of the risk in patients with stable PE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37991780</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4356>10.1001/jamacardio.2023.4356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991780</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Alfonso Muriel</dc:creator>
<dc:creator>Carmen Rodríguez</dc:creator>
<dc:creator>Sara González</dc:creator>
<dc:creator>Winnifer Briceño</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>Aitor Ballaz</dc:creator>
<dc:creator>Giuseppe Lippi</dc:creator>
<dc:creator>Roger D Yusen</dc:creator>
<dc:creator>Remedios Otero</dc:creator>
<dc:creator>David Jiménez</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients With Acute Pulmonary Embolism</dc:title>
<dc:identifier>pmid:37991780</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4356</dc:identifier>
</item>
<item>
<title>We Matched</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4254. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991769/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37991769</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4254>10.1001/jamacardio.2023.4254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991769</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Katia Bravo-Jaimes</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>We Matched</dc:title>
<dc:identifier>pmid:37991769</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4254</dc:identifier>
</item>
<item>
<title>Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 22. doi: 10.1001/jamacardio.2023.4316. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PATIENTS: This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31, 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Abbreviated (immediate DAPT discontinuation, followed by single APT for ≥6 months) or standard (DAPT for ≥2 additional months, followed by single APT for 11 months) treatment groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: One-year net adverse clinical events (NACEs) (a composite of death due to any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCEs) (a composite of death due to any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding (MCB).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 4579 patients included in the analysis, 1408 (30.7%) were women and 3171 (69.3%) were men (mean [SD] age, 76.0 [8.7] years). Ischemic and bleeding events were similar between sexes. Abbreviated DAPT was associated with comparable NACE rates in men (hazard ratio [HR], 0.97 [95% CI, 0.75-1.24]) and women (HR, 0.87 [95% CI, 0.60-1.26]; P = .65 for interaction). There was evidence of heterogeneity of treatment effect by sex for MACCEs, with a trend toward benefit in women (HR, 0.68 [95% CI, 0.44-1.05]) but not in men (HR, 1.17 [95% CI, 0.88-1.55]; P = .04 for interaction). There was no significant interaction for MCB across sex, although the benefit with abbreviated DAPT was relatively greater in men (HR, 0.65 [95% CI, 0.50-0.84]) than in women (HR, 0.77 [95% CI, 0.53-1.12]; P = .46 for interaction). Results remained consistent in patients with acute coronary syndrome and/or complex PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03023020.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991745/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37991745</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4316>10.1001/jamacardio.2023.4316</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991745</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Antonio Landi</dc:creator>
<dc:creator>Mirvat Alasnag</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Fazila Tun Nesa Malik</dc:creator>
<dc:creator>Ivan Gomez-Blazquez</dc:creator>
<dc:creator>Suzanne Pourbaix</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Christian Spaulding</dc:creator>
<dc:creator>Fermin Sainz</dc:creator>
<dc:creator>Helen Routledge</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Luca Testa</dc:creator>
<dc:creator>Alessandro Sciahbasi</dc:creator>
<dc:creator>Hussain Contractor</dc:creator>
<dc:creator>Nigel Jepson</dc:creator>
<dc:creator>Juan Mieres</dc:creator>
<dc:creator>Syed Saqib Imran</dc:creator>
<dc:creator>Husam Noor</dc:creator>
<dc:creator>Pieter C Smits</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>MASTER DAPT Investigators</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37991745</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4316</dc:identifier>
</item>
<item>
<title>AfricaSTEMI Live! 2023-a unique learning experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37991437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 22:ehad767. doi: 10.1093/eurheartj/ehad767. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37991437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37991437</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad767>10.1093/eurheartj/ehad767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37991437</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Habib Gamra</dc:creator>
<dc:creator>Bernard Gersh</dc:creator>
<dc:creator>Mohamed Jeilan</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>AfricaSTEMI Live! 2023-a unique learning experience</dc:title>
<dc:identifier>pmid:37991437</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad767</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37989571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 22:ehad774. doi: 10.1093/eurheartj/ehad774. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37989571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37989571</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad774>10.1093/eurheartj/ehad774</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37989571</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)</dc:title>
<dc:identifier>pmid:37989571</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad774</dc:identifier>
</item>
<item>
<title>Parallel neural pathways control sodium consumption and taste valence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37989313/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>The hedonic value of salt fundamentally changes depending on the internal state. High concentrations of salt induce innate aversion under sated states, whereas such aversive stimuli transform into appetitive ones under sodium depletion. Neural mechanisms underlying this state-dependent salt valence switch are poorly understood. Using transcriptomics state-to-cell-type mapping and neural manipulations, we show that positive and negative valences of salt are controlled by anatomically distinct...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 17:S0092-8674(23)01171-6. doi: 10.1016/j.cell.2023.10.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The hedonic value of salt fundamentally changes depending on the internal state. High concentrations of salt induce innate aversion under sated states, whereas such aversive stimuli transform into appetitive ones under sodium depletion. Neural mechanisms underlying this state-dependent salt valence switch are poorly understood. Using transcriptomics state-to-cell-type mapping and neural manipulations, we show that positive and negative valences of salt are controlled by anatomically distinct neural circuits in the mammalian brain. The hindbrain interoceptive circuit regulates sodium-specific appetitive drive , whereas behavioral tolerance of aversive salts is encoded by a dedicated class of neurons in the forebrain lamina terminalis (LT) expressing prostaglandin E2 (PGE2) receptor, Ptger3. We show that these LT neurons regulate salt tolerance by selectively modulating aversive taste sensitivity, partly through a PGE2-Ptger3 axis. These results reveal the bimodal regulation of appetitive and tolerance signals toward salt, which together dictate the amount of sodium consumption under different internal states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37989313/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37989313</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.020>10.1016/j.cell.2023.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37989313</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yameng Zhang</dc:creator>
<dc:creator>Allan-Hermann Pool</dc:creator>
<dc:creator>Tongtong Wang</dc:creator>
<dc:creator>Lu Liu</dc:creator>
<dc:creator>Elin Kang</dc:creator>
<dc:creator>Bei Zhang</dc:creator>
<dc:creator>Liang Ding</dc:creator>
<dc:creator>Kirsten Frieda</dc:creator>
<dc:creator>Richard Palmiter</dc:creator>
<dc:creator>Yuki Oka</dc:creator>
<dc:date>2023-11-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Parallel neural pathways control sodium consumption and taste valence</dc:title>
<dc:identifier>pmid:37989313</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.020</dc:identifier>
</item>
<item>
<title>Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37985696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 20. doi: 10.1038/s41569-023-00952-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created excitement about their potential as molecular targets for novel therapeutic approaches to treat human disease. In this Review, we focus on one category of ncRNAs - long non-coding RNAs - and their expression, functions and molecular mechanisms in cardiac hypertrophy and heart failure. We further discuss the prospects for this specific class of ncRNAs as novel targets for the diagnosis and treatment of these conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37985696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37985696</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00952-5>10.1038/s41569-023-00952-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37985696</guid>
<pubDate>Tue, 21 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>John D Mably</dc:creator>
<dc:creator>Da-Zhi Wang</dc:creator>
<dc:date>2023-11-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects</dc:title>
<dc:identifier>pmid:37985696</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00952-5</dc:identifier>
</item>
<item>
<title>Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37985192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 21;44(44):4607-4611. doi: 10.1093/eurheartj/ehad765.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37985192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37985192</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad765>10.1093/eurheartj/ehad765</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37985192</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets</dc:title>
<dc:identifier>pmid:37985192</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad765</dc:identifier>
</item>
<item>
<title>Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37983303/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 21;148(21):1677-1679. doi: 10.1161/CIRCULATIONAHA.123.066956. Epub 2023 Nov 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37983303/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37983303</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066956>10.1161/CIRCULATIONAHA.123.066956</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37983303</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Shinya Goto</dc:creator>
<dc:creator>Shinichi Goto</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis</dc:title>
<dc:identifier>pmid:37983303</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066956</dc:identifier>
</item>
<item>
<title>Atrioventricular Block: Does This Patient Require a Pacemaker?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37983302/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 21;148(21):1725-1727. doi: 10.1161/CIRCULATIONAHA.123.066813. Epub 2023 Nov 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37983302/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37983302</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066813>10.1161/CIRCULATIONAHA.123.066813</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37983302</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Esteban González-Torrecilla</dc:creator>
<dc:creator>Raquel Luna López</dc:creator>
<dc:creator>Pablo Ávila Alonso</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrioventricular Block: Does This Patient Require a Pacemaker?</dc:title>
<dc:identifier>pmid:37983302</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066813</dc:identifier>
</item>
<item>
<title>Response by de Bakker et al to Letter Regarding Article, "Sex Differences In Cardiac Troponin Trajectories Over the Life Course"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37983301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 21;148(21):1733-1734. doi: 10.1161/CIRCULATIONAHA.123.066623. Epub 2023 Nov 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37983301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37983301</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066623>10.1161/CIRCULATIONAHA.123.066623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37983301</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Marie de Bakker</dc:creator>
<dc:creator>Atul Anand</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by de Bakker et al to Letter Regarding Article, "Sex Differences In Cardiac Troponin Trajectories Over the Life Course"</dc:title>
<dc:identifier>pmid:37983301</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066623</dc:identifier>
</item>
<item>
<title>Improved Factor Combination for In Vivo Reprogramming of Cardiac Myofibroblast to Cardiomyocyte-Like Cell With Dual Recombinase Tracing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37983299/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 21;148(21):1728-1731. doi: 10.1161/CIRCULATIONAHA.122.062810. Epub 2023 Nov 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37983299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37983299</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062810>10.1161/CIRCULATIONAHA.122.062810</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37983299</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jingdong Wu</dc:creator>
<dc:creator>Hong Zhao</dc:creator>
<dc:creator>Yanmeng Tao</dc:creator>
<dc:creator>Chunyan Yang</dc:creator>
<dc:creator>Yang Yang</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Yang Zhao</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Factor Combination for In Vivo Reprogramming of Cardiac Myofibroblast to Cardiomyocyte-Like Cell With Dual Recombinase Tracing</dc:title>
<dc:identifier>pmid:37983299</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062810</dc:identifier>
</item>
<item>
<title>Letter by Esau Regarding Article, "Sex Differences in Cardiac Troponin Trajectories Over the Life Course"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37983298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 21;148(21):1732. doi: 10.1161/CIRCULATIONAHA.123.065509. Epub 2023 Nov 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37983298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37983298</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065509>10.1161/CIRCULATIONAHA.123.065509</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37983298</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniel Esau</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Esau Regarding Article, "Sex Differences in Cardiac Troponin Trajectories Over the Life Course"</dc:title>
<dc:identifier>pmid:37983298</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065509</dc:identifier>
</item>
<item>
<title>High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37982257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These exploratory findings uncover a potential role for hs-cTnI as a complementary biomarker in the prediction of preeclampsia. After validation in prospective studies, hs-cTnI, alongside maternal factors, may either be considered as a substitute for angiogenic biomarkers in health care systems where they are sparce or unavailable, or as an enhancement to established prediction models using angiogenic markers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 20. doi: 10.1161/CIRCULATIONAHA.123.066199. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Preeclampsia shares numerous risk factors with cardiovascular diseases. Here, we aimed to assess the potential utility of high-sensitivity cardiac troponin I (hs-cTnI) values during pregnancy in predicting preeclampsia occurrence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study measured hs-cTnI levels in 3721 blood samples of 2245 pregnant women from 4 international, prospective cohorts. Three analytical approaches were used: (1) a cross-sectional analysis of all women using a single blood sample, (2) a longitudinal analysis of hs-cTnI trajectories in women with multiple samples, and (3) analyses of prediction models incorporating hs-cTnI, maternal factors, and the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Women with hs-cTnI levels in the upper quarter had higher odds ratios for preeclampsia occurrence compared with women with levels in the lower quarter. Associations were driven by preterm preeclampsia (odds ratio, 5.78 [95% CI, 2.73-12.26]) and remained significant when using hs-cTnI as a continuous variable adjusted for confounders. Between-trimester hs-cTnI trajectories were independent of subsequent preeclampsia occurrence. A prediction model incorporating a practical hs-cTnI level of detection cutoff (≥1.9 pg/mL) alongside maternal factors provided comparable performance with the sFlt-1/PlGF ratio. A comprehensive model including sFlt-1/PlGF, maternal factors, and hs-cTnI provided added value (cross-validated area under the receiver operator characteristic, 0.78 [95% CI, 0.73-0.82]) above the sFlt-1/PlGF ratio alone (cross-validated area under the receiver operator characteristic, 0.70 [95% CI, 0.65-0.76]; <i>P</i>=0.027). As assessed by likelihood ratio tests, the addition of hs-cTnI to each prediction model significantly improved the respective prediction model not incorporating hs-cTnI, particularly for preterm preeclampsia. Net reclassification improvement analyses indicated that incorporating hs-cTnI improved risk prediction predominantly by correctly reclassifying women with subsequent preeclampsia occurrence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These exploratory findings uncover a potential role for hs-cTnI as a complementary biomarker in the prediction of preeclampsia. After validation in prospective studies, hs-cTnI, alongside maternal factors, may either be considered as a substitute for angiogenic biomarkers in health care systems where they are sparce or unavailable, or as an enhancement to established prediction models using angiogenic markers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37982257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37982257</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066199>10.1161/CIRCULATIONAHA.123.066199</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37982257</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>L Bacmeister</dc:creator>
<dc:creator>A Goßling</dc:creator>
<dc:creator>A Buellesbach</dc:creator>
<dc:creator>A Birukov</dc:creator>
<dc:creator>J E Myers</dc:creator>
<dc:creator>S T Thomas</dc:creator>
<dc:creator>S Lee</dc:creator>
<dc:creator>M S Andersen</dc:creator>
<dc:creator>J S Jorgensen</dc:creator>
<dc:creator>A Diemert</dc:creator>
<dc:creator>S M Blois</dc:creator>
<dc:creator>P C Arck</dc:creator>
<dc:creator>K Hecher</dc:creator>
<dc:creator>F Herse</dc:creator>
<dc:creator>S Blankenberg</dc:creator>
<dc:creator>R Dechend</dc:creator>
<dc:creator>D Westermann</dc:creator>
<dc:creator>T Zeller</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio</dc:title>
<dc:identifier>pmid:37982257</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066199</dc:identifier>
</item>
<item>
<title>Correction to: Abstract P422: Sanal Flow Choking Leads To Hemorrhagic Stroke And Other Neurological Disorders In Earth And Human Spaceflight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37982217/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 20. doi: 10.1161/RES.0000000000000645. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37982217/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37982217</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000645>10.1161/RES.0000000000000645</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37982217</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Abstract P422: Sanal Flow Choking Leads To Hemorrhagic Stroke And Other Neurological Disorders In Earth And Human Spaceflight</dc:title>
<dc:identifier>pmid:37982217</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000645</dc:identifier>
</item>
<item>
<title>Correction to: Abstract P3028: Animal In Vivo: The Proof Of Flow Choking And Bulging Of The Downstream Region Of The Stenosis Artery Due To Air Embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37982215/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 20. doi: 10.1161/RES.0000000000000646. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37982215/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37982215</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000646>10.1161/RES.0000000000000646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37982215</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Abstract P3028: Animal In Vivo: The Proof Of Flow Choking And Bulging Of The Downstream Region Of The Stenosis Artery Due To Air Embolism</dc:title>
<dc:identifier>pmid:37982215</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000646</dc:identifier>
</item>
<item>
<title>One or 3 months dual antiplatelet therapy in high bleeding risk patients: splitting hair or aiming at the bullseye?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37981898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 20:ehad729. doi: 10.1093/eurheartj/ehad729. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37981898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37981898</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad729>10.1093/eurheartj/ehad729</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37981898</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Francesco Costa</dc:creator>
<dc:creator>Claudio Montalto</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>One or 3 months dual antiplatelet therapy in high bleeding risk patients: splitting hair or aiming at the bullseye?</dc:title>
<dc:identifier>pmid:37981898</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad729</dc:identifier>
</item>
<item>
<title>What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention in high-bleeding risk: 1 month or 3 months?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37981875/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 20:ehad728. doi: 10.1093/eurheartj/ehad728. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37981875/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37981875</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad728>10.1093/eurheartj/ehad728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37981875</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yuqin Zhao</dc:creator>
<dc:creator>Yafang Chen</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention in high-bleeding risk: 1 month or 3 months?</dc:title>
<dc:identifier>pmid:37981875</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad728</dc:identifier>
</item>
<item>
<title>Finding a network of support: Ukrainian doctor's experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37981857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 20:ehad496. doi: 10.1093/eurheartj/ehad496. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37981857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37981857</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad496>10.1093/eurheartj/ehad496</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37981857</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Oksana Marchenko</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Finding a network of support: Ukrainian doctor's experience</dc:title>
<dc:identifier>pmid:37981857</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad496</dc:identifier>
</item>
<item>
<title>Beyond association: high neutrophil counts are a causal risk factor for atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37981833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231122131058&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 20:ehad711. doi: 10.1093/eurheartj/ehad711. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37981833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231122131058&v=2.17.9.post6+86293ac">37981833</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad711>10.1093/eurheartj/ehad711</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37981833</guid>
<pubDate>Mon, 20 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Oliver Soehnlein</dc:creator>
<dc:creator>Yvonne Döring</dc:creator>
<dc:date>2023-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beyond association: high neutrophil counts are a causal risk factor for atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:37981833</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad711</dc:identifier>
</item>





























</channel>
</rss>